Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cisplatin
Drug ID BADD_D00474
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status approved
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 5702198
TTD Drug ID D0U5HU
NDC Product Code 16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII Q20Q21Q62J
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula PtCl2(NH3)2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt]Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bladder perforation20.03.01.005; 12.02.10.0010.000112%
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.004264%Not Available
Tumour invasion16.16.01.0080.000112%Not Available
Osteonecrosis of jaw24.04.05.005; 15.02.04.0100.000772%
Infusion site extravasation12.07.05.008; 08.02.05.0070.000112%
Chronic kidney disease20.01.03.0170.000504%
Immune reconstitution inflammatory syndrome08.06.02.014; 10.02.01.0430.000112%Not Available
Bone marrow failure01.03.03.0050.002350%
Pharyngeal inflammation22.04.05.0080.000112%
Cytopenia01.03.03.0120.000168%Not Available
Liver injury12.01.17.012; 09.01.07.0220.000168%Not Available
Hyperammonaemic encephalopathy17.13.01.005; 14.10.01.0060.000168%Not Available
Organising pneumonia22.01.02.0080.000168%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.0080.000112%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.002597%
Vulvovaginal pain21.08.02.0090.000112%
Acute kidney injury20.01.03.0160.007611%
Posterior reversible encephalopathy syndrome17.13.02.0070.000616%
Peripheral artery thrombosis24.01.02.0100.000224%Not Available
Hepatocellular carcinoma16.07.02.005; 09.04.02.0100.000224%Not Available
Reversible cerebral vasoconstriction syndrome24.04.06.026; 18.06.01.004; 17.08.02.0140.000224%Not Available
Genitourinary symptom21.10.01.014; 20.08.01.0080.000112%Not Available
Perforation08.01.03.0580.000224%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000783%
Anal incontinence17.05.01.021; 07.01.06.0290.000112%
Adenocarcinoma gastric16.13.03.002; 07.21.02.0020.000168%Not Available
Anaemia of chronic disease01.03.04.0020.000112%Not Available
Breast cancer recurrent21.05.01.017; 16.10.01.0090.000168%Not Available
Cardiac failure chronic02.05.01.0090.000168%Not Available
Chloroma16.01.08.003; 01.10.08.0030.000112%Not Available
The 17th Page    First    Pre   17 18 19 20    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene